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Low-molecular-weight heparin in patients with advanced cancer: A
phase 3 clinical trial
Sideras K, Schaefer PL, Okuno SH, et al. Mayo Clin Proc 2006;81:758-67.
Conclusion: Low-molecular-weight heparin does not provide survival
benefit in patients with advanced cancer.
Summary: It has been suggested that patients with cancer who develop
venous thromboembolism (VTE) and are treated with low-molecular-
weight heparin have a survival advantage over those treated with unfraction-
ated heparin (Am J Med 1996;100:269-277 and Ann Intern Med 1999;
130:800-809). The authors therefore sought to assess whether low-
molecular-weight heparin might provide a survival advantage in patients
with advanced cancer.
This was a randomized clinical trial conducted between December
1998 and June 2001. Patients with advanced cancer were randomized to
receive low-molecular-weight heparin or placebo. The study began as a
double-blinded placebo-controlled trial with patients receiving injections
daily of saline or 5000 U of low-molecular-weight heparin. Recruitment for
the trial was low; therefore, the placebo arm was eliminated midway through
the study. At this point, the study became open labeled, and patients
received low-molecular-weight heparin injections and standard clinical care,
or standard clinical care alone. The primary study end point was overall
survival.
There were 138 patients analyzed. Median survival for the combined
standard-care and placebo groups was 10.5months (95% confidence interval
[CI], 7.6 to 12.2 months). Median survival for the low-molecular-weight
heparin arms of the trial was 7.3 months (95% CI, 4.8 to 12.2). This was not
significantly different from the placebo group (P  .46). Median survival
times for unblinded and blinded low-molecular-weight heparin groups were
9.0 months and 6.2 months, respectively. Median survival time was 10.5
months in the standard-care group and 10.3 months in the placebo-blinded
group. There was a 6% rate of significant VTE in the low-molecular-weight
heparin arms and a 7% rate in the control arms. Major bleeding was 7% in the
control arms and 3% in the low-molecular-weight heparin arms.
Comment: It has been suggested for a number of years that low-
molecular-weight heparin may confer a survival advantage over unfraction-
ated heparin in patients with VTE and cancer. A pleiotropic effect of
low-molecular-weight heparin was postulated. This study argues against
such an effect. Weaknesses of the study include changing its design in
mid-course and inclusion of four different groups of cancer patients, perhaps
masking a treatment effect in one group vs another. The trial did demon-
strate safety of low-molecular-weight heparin in patients with advanced
cancer.
Determinants of arterial wall remodeling during lipid-lowering ther-
apy: Serial intravascular ultrasound observations from the reversal of
atherosclerosis with aggressive lipid Lowering therapy (REVERSAL)
trial
Schoenhagen P, Tuzcu EM, Apperson-Hansen C, et al. Circulation 2006;
113:2826-34.
Conclusion: Plaque stabilization therapy with statin medications re-
sults in constrictive remodeling of the arterial wall and appears related to the
anti-inflammatory effects of statin medications.
Summary: The authors sought to study remodeling of coronary arter-
ies during plaque-stabilizing therapy and to relate this remodeling to mark-
ers of lipid metabolism and inflammation.
The Reversal of Atherosclerosis with Aggressive Lipid Lowering Ther-
apy (REVERSAL) trial examined reversal of coronary artery atherosclerosis
during 18 months of intensive vs moderate lipid-lowering therapy. The
authors identified 210 patients with mild luminal narrowing coronary le-
sions. External elastic membrane (EEM) area, lumen area, and plaque area
were determined at the site of the coronary lesions and at a reference site
proximal to the lesions. Measurements were taken at baseline and during
follow-up. The remodeling ratio (RR) was calculated by dividing EEM area
of the lesion by EEM reference area. Changes in remodeling and changes in
plaque area were correlated with lipid profile and inflammatory markers.
The lesions examined showed a progression in plaque area (8.9% 
25.7%) and a decrease in RR (3.0%  11.2%) during follow-up. Direct
effects with RR were correlated with percentage change in plaque area (P
.0001), baseline RR (P .0001), and baseline lesion lumen area (P .019)
as well as change in high sensitivity C-reactive protein levels (P .027) and
baseline hypertension (P .014). Age (P .037) and percentage change in
triglyceride levels (P  .049) demonstrated significant inverse relationships
with RR during follow-up. There were no associations between changes in
treatment group (moderate vs high-intensity statin therapy) levels of low-
density (LDL) or high-density lipoprotein (HDL) cholesterol.
Comment: Plaque regression and stabilization appears to be accompa-
nied by a reduction in vessel size. Correlation of these effects with C-reactive
protein, but not serum levels of HDL or LDL cholesterol, suggest drugs
targeting arterial inflammation may be more effective than those targeting
simple measures of lipid metabolism. The anti-inflammatory effects of statins
may turn out to be more important than their cholesterol-lowering effects.
Incidence of new brain lesions after carotid stenting with and without
cerebral protection
Kastrup A, Nagele T, Groschel K, et al. Stroke 2006; 36:2312-6.
Conclusion: New cerebral infarcts detected by diffusion-weighted
imaging (DWI) are common after protected and unprotected carotid artery
stenting, but fewer DWI lesions occur after protected carotid artery stenting.
Summary: DWI is currently the most sensitive tool to detect early
cerebral ischemia (Stroke 1998;29:1783-90). In this study, the authors used
DWI to compare the number, frequency, and size of new DWI lesions after
protected and unprotected carotid artery stenting and sought to determine
the clinical significance of these lesions. DWI was obtained before carotid
artery stenting and 48 hours after carotid artery stenting. Clinical end
points included stroke and death 30 days.
There were 139 patients treated with protected and 67 patients treated
with unprotected carotid artery stenting. After protected carotid artery
stenting, the proportion of patients with new ipsilateral DWI lesions was
lower than after unprotected carotid artery stenting (49% vs 67%; P  .05).
The number of new ipsilateral DWI lesions was also lower after protected vs
unprotected carotid artery stenting (median, 0 [interquartile range, 0 to 0.3]
vs median, 1 [interquartile range, 0 to 4]; P  .05). Most of the new DWI
lesions were asymptomatic and10 mm in diameter. The clinical outcomes
of patients treated with cerebral protection at 30 days did not differ signifi-
cantly from those with patients not treated with cerebral protection (4.3%
stroke and death vs 7.5% stroke and death, P  NS). The number of new
DWI lesions was, however, significantly higher in patients with postproce-
dure stroke (median, 7.5 [interquartile range, 1.5 to 17]) vs patients without
stroke (median, 0 [interquartile range, 1 to 3.25]; P  .01).
Comment: Carotid artery stenting results in a large number of silent
cerebral infarcts. Most are asymptomatic, but the number of DWI infarcts
correlates with clinical stroke. This suggests that detection of DWI infarcts
may be a reasonable surrogate end point for comparison of cerebral produc-
tion devices used in carotid artery stenting.
Silent ischemia after neuroprotected percutaneous carotid stenting: A
diffusion-weighted MRI study
Pinero P, Gonzalez A, Mayol A, et al. AJNR Am J Neuroradiol 2006;27:
1338-45.
Conclusions: New ischemic foci detected by diffusion-weighted im-
aging (DWI) occurred in 17% of cases after carotid artery stenting. DWI
lesions did not correlate with microemboli signals detected by transcranial
Doppler, but did correlate with occurrence of transient ischemic attack
(TIA).
Summary: Carotid artery stenting using a distal filter embolic protec-
tion device was performed in 162 patients (75.3% symptomatic). Four
different types of embolic protection devices were used: EPI and EZ filter
wires (Boston Scientific/Target Therapeutics, Fremont, Calif), Spider (ev3,
Plymouth, Minn), and Accunet (Guidant, Santa Clara, Calif). DWI was
performed72 hours of carotid artery stenting and 24 hours after stenting.
Middle cerebral artery transcranial Doppler ultrasonography was used to
monitor 95 (58.6%) of the 162 patients to detect microemboli ipsilateral to
the stented carotid artery.
After stenting, 28 patients (7.3%) showed 58 new DWI ischemic
lesions, and 13 (46.4%) had multiple DWI lesions. A total of 67.9% of new
lesions were in the vascular territory supplied by the carotid artery treated.
DWI lesions also occurred in the contralateral middle cerebral artery in one
patient and in the posterior fossa of four patients. The appearance of new
DWI lesions and the occurrence of TIA was significantly correlated (P 
.03). Of the patients studied with transcranial Doppler, microembolic
signals were detected in 92.6%. There was no relationship between micro-
embolic signals and new DWI lesions. There was also no relationship
between new DWI lesions and patient demographics, clinical presentation,
vascular risk factors, plaque characteristics, or type of stent or cerebral
protection device.
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Comment: This is another report documenting a high rate of new
ischemic foci after carotid artery stenting. Clearly, there is room for improve-
ment in the design of neuroprotection devices as adjuncts to carotid artery
stenting.
Familial thoracic aortic aneurysms and dissections--incidents, modes of
inheritance, and phenotypic patterns
Albornoz G, Coady MA, Roberts M, et al. Ann Thorac Surg 2006;82:
1400-6.
Conclusion: Thoracic aortic aneurysms (TAAs) are frequently familial,
with an autosomal dominant pattern of inheritance and a growth rate higher
rate than that in nonfamilial TAAs.
Summary: The authors studied phenotypic and genetic patterns of
TAAs and dissections. The authors identified 520 patients with TAA and
examined their pedigrees to identify family members with aneurysms. Pa-
tients were examined for age of presentation, familial clustering of aneu-
rysms, rate of aneurysm growth, and hypertension as well as a correlation of
aneurysm sites among kindred and pedigree inheritance patterns.
There was an inherited pattern for TAA in 21.5% of non-Marfan
patients. This pattern was primarily autosomal dominant (76.9%), with
varying degrees of expression and penetrance. Patients with familial TAAs
were younger than those with sporadically occurring TAAs (P .0001), but
was not as young as the Marfan patients (mean age, 58.2 vs 65.7 vs 27.4
years, P  .001. There were 197 patients with kindred aneurysms and TAA
was present in 131 (66.5%). Abdominal aortic aneurysms (AAA) were
present in 49 patients (24.9%), and 17 (8.6%) had either cerebral or other
aneurysms. Hypertension and AAA were associated more with descending
than ascending TAA (P .001). The highest rate of aortic growth occurred
in the patients with a familial pattern of TAA (0.21 cm/year). Growth was
intermediate in patients with sporadically occurring TAA (0.16 cm/year).
Aneurysm growth was lowest in the Marfan patients (0.1 cm/year, P 
0.01).
Comment: A familial pattern of AAA has been long recognized.
Surprisingly, relatively few previous studies have examined familial predis-
position to TAA and thoracic aortic dissection. The important points of this
article are that many TAAs and dissections are familial (20% of non-Marfan
patients). In addition, patients with a familial pattern of TAA have a higher
rate of aneurysm growth than those with sporadic disease. The data suggest
screening for aneurysm disease in first-order relatives and probans of patients
with TAA
Management and hospital outcomes of blunt renal artery injuries:
Analysis of 517 patients from the national trauma data bank
Sangthong B, Demetrios D, Martin M, et al. J Am Coll Surg 2006;203:
612-7.
Conclusion: Nonoperative management is an acceptable therapeutic
option for blunt renal artery trauma.
Summary: Blunt injuries to the renal artery are rare. The authors
sought to evaluate current therapeutic approaches to blunt renal artery
trauma, with emphasis on the effect of various therapies and on hospital
outcomes. Data from the National Trauma Data Bank were reviewed.
Patients with blunt trauma admissions who had renal artery injuries were
included. Data analyzed included patient demographics, Injury Severity
Score, Abbreviated Injury Severity Score for each body area, mechanism of
injury, type of management of blunt renal artery trauma (arterial reconstruc-
tion, nephrectomy, or observation), and in-hospital outcomes, including
intensive care unit stay, total hospital days, and mortality. The relationship
between type of management and hospital outcome was examined with
multiple and logistic regression analysis.
The database included 945,326 blunt trauma admissions, of which
only 517 (0.05%) had documented injuries to the renal artery. In 373
patients (73%), the kidney was not explored. Immediate nephrectomy was
performed in 95 patients (18%), and 45 (9%) underwent surgical revascular-
ization. In 87 (17%) of the 517 patients with renal artery injury, renal artery
injury was the only intra-abdominal injury. Of these, 73 (84%) were treated
nonoperatively, and seven (8%) had early nephrectomy. Longer hospital
stays were associated with surgical revascularization and nephrectomy. Sur-
gical revascularization was also associated with longer intensive care unit
stay.
Comment: The rarity of blunt renal artery injury, time constraints,
complexity of repair, and reported poor outcomes (Tech Urol 1998;4:1-11)
all combine to make repair of the blunt renal artery injury a rare event.
Nevertheless, in appropriately stable patients, a renal artery injury to a single
functioning kidney or bilateral renal artery occlusion after blunt trauma
should be considered for repair in an attempt to avoid permanent dialysis.
Vessel wall calcifications with multi-detector row CT angiography in
patients with peripheral arterial disease: Effect on clinical utility and
clinical predictors
Ouwendijk R, KockMCJM, van Dijk LC, et al. Radiology 2006:241;603-8.
Conclusions:The clinical utility of computed tomography CT angiog-
raphy (CTA) is decreased by vessel wall calcification. Vessel wall calcification
is predicted by the presence of diabetes, cardiac disease, and increased age.
Summary: CTA is an alternative to magnetic resonance angiography
and contrast angiography for evaluation of peripheral arterial disease. Mod-
ern CT scanners with improved multidetector row technology have lower
dose requirements of contrast medium, improved spatial resolution of small
arterial branches, shorter acquisition times, and increased volume coverage.
A potential drawback of CTA, however, is calcification. Calcification of
arterial walls, particularly in small arteries, can result in high attenuation
artifacts leading to a false-positive diagnosis of stenosis and to false-negative
findings of patency. The authors sought to evaluate the effect of vessel wall
calcification on the clinical utility of CTA and identify predictors of vessel
wall calcification.
This was a retrospective study of patients from randomized trials
evaluating the cost of diagnostic imaging of patients with peripheral arterial
disease. The clinical utility of CT angiograms was measured using a rating of
therapeutic confidence (10-point scale) and need for additional vascular
imaging. The effect of vessel wall calcification on the clinical utility of CTA
and patient characteristics correlating with the number of calcified segments
on CTA were determined.
The study included 145 patients (mean age 64 years, 70% men). The
number of calcified segments predicted confidence scores (P  .001) and
need for additional imaging (P  .001). It was possible to discriminate
between patients who required additional imaging after CTA by the number
of calcified segments. Age84 years, cardiac disease, and diabetes predicted
increased numbers of calcified segments (P  .05).
Comment:All imaging techniques have advantages and disadvantages.
A clear disadvantage of CTA is the evaluation of small, heavily calcified
arteries. The study suggests that despite its lower costs and noninvasive
nature, other forms of arterial imaging such as magnetic resonance angiog-
raphy or contrast angiography should be considered in patients with diabe-
tes, heart disease, and advanced age who require operative intervention of
smaller arteries.
Acute limb ischemia associated with type B aortic dissection: Clinical
relevance and therapy
Henke PK, Williams DM, Upchurch GR Jr, et al. Surgery 2006;140:532-
40.
Conclusion: In patients with aortic dissection, both death and visceral
ischemia are associated with acute limb ischemia. Excellent limb salvage can
be achieved with endovascular therapy, which also allows diagnosis of
previously unsuspected visceral ischemia.
Summary: The authors sought to characterize presentation, therapy,
and outcomes of patients with type B aortic dissection and acute limb
ischemia. Data from the prospective/retrospective International Registry for
Acute Aortic Dissection (IRAD) and from the University of Michigan were
queried for all patients with type B aortic dissection from 1996 to 2002. The
IRAD Database contained 458 patients (70% men) with a mean age of 64
years. Overall mortality was 12%; and of these, 6% had acute limb ischemia.
Pulse deficits and neurologic deficits were more common in patients with
acute limb ischemia after aortic dissection than in those without acute limb
ischemia (P .001). There was no difference in age, race, gender, or origin
of the dissection in the patients with type B dissection and acute limb
ischemia vs those with type B dissection without limb ischemia.
Acute limb ischemia in patients with type B aortic dissection was
associated with an increased risk of acute renal failure (odds ratio [OR], 2.7;
95% confidence interval [CI], 1.1 to 7.1; P  .48), acute mesenteric
ischemia or infarction (OR, 6.9; 95% CI, 2.5 to 20; P  .001); and, when
adjusting for patient characteristics, was also associated with death (OR, 3.5;
95% CI, 1.1 to 20; P  .02). There were similar patient demographics and
mortality in 93 patients with acute type B dissection analyzed during the
same period at theUniversity ofMichigan, with 28 patients also having acute
limb ischemia. Aortic fenestration or aortic iliac stenting were used to treat
93% and surgical bypass was used in 7%. At a mean of 18 months, limb
salvage was 93%. Impaired organ system perfusion was two times higher at
angiography than was clinically suspected before angiography (P  .002).
Comment: The main points to be taken from this report are that
endovascular therapy works well for treatment of acute limb ischemia in
patients with type B aortic dissection and other unsuspected areas of im-
paired organ perfusion will be discovered at the time of aortography.
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